Open Access Highly Accessed Research article

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Sibilia Quilici1, Jeremy Chancellor2*, Mickael Löthgren3, Dominique Simon4, Gérard Said5, Trong Kim Le6, Ana Garcia-Cebrian7 and Brigitta Monz8

Author Affiliations

1 Health Economics & Outcomes Research, i3 Innovus, Uxbridge, UK

2 Health Economics & Outcomes Research, i3 Innovus, Uxbridge, UK

3 Innovus Research (UK) Ltd, High Wycombe, UK

4 Service de Diabétologie, Hôpital de la Pitié, Paris, France

5 Service de Neurologie, Hôpital le Kremlin Bicêtre, Paris, France

6 Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA

7 European Health Outcomes, Eli Lilly and Company Limited, Windlesham, Surrey, UK

8 Global Health Economics & Outcomes Research, Boehringer Ingelheim GmbH, Ingelheim, Germany

For all author emails, please log on.

BMC Neurology 2009, 9:6  doi:10.1186/1471-2377-9-6

Published: 10 February 2009



Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and tolerability of DLX with PGB and GBP in DPNP, using placebo as a common comparator.


We searched PubMed, EMBASE, CENTRAL databases and regulatory websites for randomized, double-blind, placebo-controlled, parallel group or crossover clinical trials (RCTs) assessing DLX, PGB, GBP and AMT in DPNP. Study arms using approved dosages with assessments after 5–13 weeks were eligible. Efficacy criteria were: reduction in 24-hour pain severity (24 h PS) for all three drugs, and response rate (≥ 50% pain reduction) and Patient Global Impression of Improvement/Change (PGI-I/C) for DLX and PGB only. Tolerability criteria included: discontinuation, diarrhoea, dizziness, headache, nausea and somnolence. Direct comparisons versus placebo were conducted with pooled fixed – and random-effects analyses on endpoints reported in at least two studies of each drug. Indirect comparisons were performed between DLX and each of PGB and GBP using Bayesian simulation.


Three studies of DLX, six of PGB, two of GBP and none of AMT met the inclusion criteria. In random-effects and fixed-effects analyses of DLX, PGB and GBP, all were superior to placebo for all efficacy parameters, with some tolerability trade-offs. Indirect comparison of DLX with PGB found no differences in 24 h PS, but significant differences in PGI-I/C, favouring PGB, and in dizziness, favouring DLX were apparent. Comparing DLX and GBP, there were no statistically significant differences.


From the few available studies suitable for indirect comparison, DLX shows comparable efficacy and tolerability to GBP and PGB in DPNP. Duloxetine provides an important treatment option for this disabling condition.